Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

12.00 +0.15 (+1.27%)

Streaming Delayed Price Updated: 3:51 PM EDT, May 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2

...

26 27 28 29 30 31 32 33 Next >

Breaking the Habit: Psychedelic Stigma Fades as Research Points to Critical Use in Smoking Cessation and More

November 01, 2021

Via Investor Brand Network

Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent ↗

October 26, 2021

The Week In Psychedelics

Via Benzinga

Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148% ↗

October 24, 2021

The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021 ↗

October 29, 2021

Upgrades For Preferred Bank (NASDAQ:

Via Benzinga

Psychedelics Industry Moving Full-Speed Ahead, When Will Stocks Catch Up? ↗

October 23, 2021

The psychedelic drug industry is advancing by leaps and bounds, but the stocks have been sliding. Why this disconnect won't last.

Via Talk Markets

Down 25% in 2021, Is Compass Pathways Undervalued? ↗

October 22, 2021

It depends on how optimistic you are about its lead program.

Via The Motley Fool

North America Continues Leading The Way In Psychedelic Wellness

October 26, 2021

Palm Beach, FL –October 26, 2021 – FinancialNewsMedia.com News Commentary – The global psychedelic drugs market remains at an early stage in its life cycle, with most companies currently developing...

Via FinancialNewsMedia

Phase 2 Trial On Ayahuasca's Active Ingredient Puts Small Pharma On Track To Winning The Psychedelics Race ↗

October 20, 2021

Small Pharma Inc. (OTCQB:DMTTF) (TSXV:

Via Benzinga

Psychedelic Unicorn Compass Pathways Receives New Patent Approval ↗

October 20, 2021

Compass Pathways (NASDAQ:CMPS), a unicorn company in the psychedeli...

Via Benzinga

Topics Intellectual Property

Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation ↗

October 18, 2021

The Week In Psychedelics

Via Benzinga

This Company Just Extended its Reach into the United Kingdom by Opening its First Ketamine Therapy Clinic ↗

October 18, 2021

Photo by cottonbro from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner...

Via Benzinga

A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector

October 18, 2021

FN Media Group Presents Oilprice.com Market Commentary London – October 18, 2021 – A massive disruption now appears imminent in one of the world’s largest – and most important – industries. In much the...

Via FinancialNewsMedia

Topics Artificial Intelligence

Forget The Hype: The Psychedelic Stocks Sector Went Down In The Third Quarter Of 2021 ↗

October 15, 2021

Despite the prevailing hype, the psychedelic sector went down considerably last quarter (July through September) and has gone down even further so far this month.

Via Talk Markets

There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are ↗

October 13, 2021

Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...

Via Benzinga

Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations ↗

October 12, 2021

Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets.

Via Talk Markets

U.S. Is Dominating Psychedelic Drugs Market Due To Growing Acceptance For Treating Depression & Rise In Product Approvals

October 12, 2021

Palm Beach, FL –October 12, 2021 – FinancialNewsMedia.com News Commentary – After being relegated to the margins of sincere scientific examination for about the last several decades, growing...

Via FinancialNewsMedia

Why Compass Pathways Stock Dropped 12% in September ↗

October 05, 2021

Progress continues on the company's work to develop a mental health treatment using a psychoactive drug therapy.

Via The Motley Fool

NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Therapeutic Options to Diseases with Unmet Needs

September 30, 2021

Via Investor Brand Network

Topics Cannabis

Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028

October 11, 2021

Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,...

Via FinancialNewsMedia

Psychedelics Renaissance Underway as Paradigm Shifting Cure for Depression Potentially Discovered

September 28, 2021

Via FinancialNewsMedia

Topics Law Enforcement

Investors Turning to Psychedelic Market as Renaissance Continues into New Wave of Diseases

September 27, 2021

Via Investor Brand Network

Topics Cannabis

Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market

October 05, 2021

Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to...

Via FinancialNewsMedia

1 Recent Healthcare IPO to Put on Your Radar ↗

September 24, 2021

Here's a pharmaceutical company that could have an incredibly bright future.

Via The Motley Fool

Topics Initial Public Offering

Is Ketamine A Psychedelic? Depends On Who You Ask ↗

September 22, 2021

Ketamine, an FDA-approved anesthetic drug, has recently become the star of the psychedelic medicine movement. As p...

Via Benzinga

Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts

September 22, 2021

Via FinancialNewsMedia

The Three Psychedelics ETFs: Which Is The Best Fit For Your Portfolio? ↗

September 21, 2021

We compare and contrast the three psychedelic drug ETFs and assess which investor needs each addresses.

Via Talk Markets

Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial ↗

September 20, 2021

AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares

Via Benzinga

Which Psychedelic Stock ETF Is Right For You? ↗

September 18, 2021

This week the AdvisorShares Psychedelics ETF began trading on the NYSE Arca. Here we compare the make-up of the now 3 psychedelic stock ETFs and two tracking indexes.

Via Talk Markets

Compass: Psychedelics Unicorn Expands Portfolio Beyond Psilocybin Into Psychedelics 2.0 ↗

September 15, 2021

Psychedelics biotech company Compass Pathways (NASDAQ:CMPS...

Via Benzinga

Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry? ↗

September 09, 2021

By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate...

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.